A multidisciplinary approach for autologous breast reconstruction: A narrative (re)view for better management

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

  • Orit Kaidar-Person, Sheba Medical Center at Tel Hashomer, Maastricht University, Tel Aviv University
  • ,
  • Naama Hermann, Tel Aviv University, Sheba Medical Center at Tel Hashomer
  • ,
  • Philip Poortmans, Iridium Kankernetwerk, University of Antwerp
  • ,
  • Birgitte V. Offersen
  • Liesbeth J. Boersma, Maastricht University
  • ,
  • Dirk de Ruysscher, Maastricht University
  • ,
  • Trine Tramm
  • Thorsten Kühn, Klinikum Esslingen
  • ,
  • Tine Engberg Damsgaard
  • Oreste Gentilini, San Raffaele University
  • ,
  • Wies Maarse, Utrecht University
  • ,
  • Miri Sklair-Levi, Tel Aviv University, Sheba Tel Hashomer
  • ,
  • Zoltán Mátrai, National Institute of Oncology

Breast reconstruction and oncoplastic surgery have become an important part of breast cancer care. The use of autologous breast reconstruction (ABR) has evolved significantly with advances in microsurgery, aiming to reduce donor site complications and improve cosmesis. For years, immediate-ABR was considered a contraindication if postmastectomy irradiation (PMRT) was planned. As a result of de-escalation of axillary surgery the indication of PMRT are increasing along-side with observations that PMRT in the setting of ABR is not contraindicated. Surgical techniques may result in different amount and areas of breast residual glandular tissue and patient selection is important to reduce potential residual disease. Meticulus radiation planning is important to potentially reduce complications without compromising oncologic outcomes. Surgical techniques change constantly in aim to improve aesthetic results but should most importantly maintain priority to the oncological indications. By multidisciplinary team work with a comprehensive understanding of each discipline, we can preserve the accomplishments of breast surgery in the setting of PMRT, without compromising disease control.

TidsskriftRadiotherapy and Oncology
Sider (fra-til)263-271
Antal sider9
StatusUdgivet - apr. 2021

Se relationer på Aarhus Universitet Citationsformater

ID: 220138489